DDX21 and colorectal cancer: Specifically focusing on candidate proteins that have known antigenic properties, we selected DDX21 and investigated the protein expression of DDX21 in a large cohort of 619 patients with early stage colorectal cancer and a small cohort of 91 patients with late stage colorectal cancer (Figs. 2, 3).